In response to the growing concerns over the dependence on foreign drug manufacturing, the FDA has launched the innovative PreCheck program. This two-phase initiative is designed to streamline facility approvals, reduce reliance on overseas pharmaceutical production, and enhance the resilience of the domestic drug supply chain. By fortifying regulatory processes and encouraging the establishment of manufacturing facilities within the United States, the PreCheck program aims to address national security risks associated with the current overreliance on foreign sources for pharmaceuticals.
The inception of FDA PreCheck follows the implementation of Executive Order 14293, emphasizing the necessity to facilitate the review of domestic pharma production, eliminate unnecessary regulatory hurdles, and improve the efficiency of regulatory reviews. The program consists of two key phases, offering a comprehensive approach to support the establishment of new drug manufacturing facilities in the US. This strategic move is crucial in light of the fact that a significant proportion of active pharmaceutical ingredients (APIs) used in the US are sourced from foreign manufacturers, with only a limited number of API producers based domestically.
The initial phase of the PreCheck program, known as the Facility Readiness Phase, involves providing essential communication and guidance to pharmaceutical manufacturers at critical stages of facility development. This phase encourages companies to share detailed facility-specific information through a Type V Drug Master File (DMF), enabling the FDA to better assess facility design, construction, and pre-production activities. The subsequent Application Submission Phase focuses on expediting the review process by offering early feedback on the “Chemistry, Manufacturing, and Controls” section of the application.
The escalating tariffs and trade tensions have further accelerated efforts to reshore manufacturing operations back to the US. With the imposition of significant tariffs on pharmaceutical imports, several major companies, including Regeneron, Roche, Merck, and Thermo Fisher, have committed substantial investments to enhance their manufacturing and research capabilities within the country. These strategic investments are aimed at mitigating the impact of tariffs and strengthening the domestic drug manufacturing landscape.
Looking ahead, the FDA is set to host a public meeting titled “Onshoring Manufacturing of Drugs and Biological Products” to discuss the draft FDA PreCheck framework, engage stakeholders in discussions on its effectiveness, and explore additional strategies to address current challenges in onshoring drug manufacturing operations. This collaborative effort underscores the commitment of regulatory authorities and industry stakeholders to foster a robust and resilient drug manufacturing ecosystem within the United States.
Key Takeaways:
– The FDA’s PreCheck program is a strategic initiative aimed at strengthening the US drug manufacturing landscape and reducing reliance on foreign sources.
– The two-phase approach of the PreCheck program focuses on streamlining facility approvals and expediting the regulatory review process for new drug manufacturing facilities.
– The escalating tariffs and trade tensions have prompted pharmaceutical companies to invest significantly in reshoring manufacturing operations back to the US.
– The upcoming FDA public meeting on onshoring drug manufacturing highlights the collaborative efforts to enhance the resilience and sustainability of the domestic drug supply chain.
Tags: regulatory, automation
Read more on pharmaceuticalcommerce.com